Clazakizumab in late antibody-mediated rejection: study protocol of a randomized controlled pilot trial

BACKGROUND: Late antibody-mediated rejection (ABMR) triggered by donor-specific antibodies (DSA) is a cardinal cause of kidney allograft dysfunction and loss. Diagnostic criteria for this rejection type are well established, but effective treatment remains a major challenge. Recent randomized contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Eskandary, Farsad, Dürr, Michael, Budde, Klemens, Doberer, Konstantin, Reindl-Schwaighofer, Roman, Waiser, Johannes, Wahrmann, Markus, Regele, Heinz, Spittler, Andreas, Lachmann, Nils, Firbas, Christa, Mühlbacher, Jakob, Bond, Gregor, Halloran, Philipp F., Chong, Edward, Jilma, Bernd, Böhmig, Georg A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329051/
https://www.ncbi.nlm.nih.gov/pubmed/30635033
http://dx.doi.org/10.1186/s13063-018-3158-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329051/
https://www.ncbi.nlm.nih.gov/pubmed/30635033
http://dx.doi.org/10.1186/s13063-018-3158-6

Ejemplares similares